NASDAQ:GMAB
Genmab ADR (GMAB)
Financials 
Technical Analysis 
Jul 24, 2026, 12:00 amThis summary was created by AI, based on 3 opinions in the last 12 months.
Genmab ADR (GMAB-Q) is a biotech company based in the Netherlands, primarily focused on developing human antibody treatments for cancer. Recent earnings reports show promising signs, as revenues increased by 19%, largely driven by a 54% rise in sales of proprietary cancer treatments. Analysts highlight a robust financial position, with cash reserves growing and a notable reduction in debt due to a lucrative royalty agreement with J&J worth $14.3 billion. Despite a past recommendation to exit the position due to a triggered stop loss at $24, current analysts maintain a strong bullish outlook, reiterating GMAB as a top pick with significant upside potential based on favorable price targets which suggest a robust growth trajectory in the coming years.
;fill-opacity:1;'/%3e%3cpath%20d='M31%2018.6001V30H8V18.6001L14.1334%2022.4334L19.4999%2014L24.8669%2022.4334L31%2018.6001Z'%20fill='%23EE5432'%20style='fill:%23EE5432;fill:color(display-p3%200.9340%200.3310%200.1956);fill-opacity:1;'/%3e%3c/svg%3e){kind=small}
Premium content
Premium contentFollowing recently released earnings, we reiterate GMAB as a TOP PICK. The Danish based pharmaceutical company reported a 19% increase in revenues, thanks to a 54% increase in the sales of proprietary antibody treatments for cancer. Cash reserves grew while shares were aggressively bought back. It trades at 18x earnings, 3x book and supports a 17% ROE. We continue to recommend a stop at $24, looking to achieve $37 — upside potential of 32%. Yield 0%
(Analysts’ price target is $36.75)Premium contentGMAB is a biotech company based in the Netherlands producing human antibody treatments for cancer. It collects a royalty agreement with J&J that pays $14.3 billion, of which over half originates from the US and the balance from Europe. This is allowing for cash reserves to grow aggressively, while debt is retired. Annual EPS growth exceeds 28% over the past five years and analysts see growth over 20% over the next five. It trades at 16x earnings, 3.2x book and supports a 28% ROE. We recommend setting a stop-loss at $24, looking to achieve $37 -- upside potential of 23%. Yield 0%
(Analysts’ price target is $37.42)- «
- ‹
- 1
- ›
- »
Popular Articles
Genmab ADR (GMAB) Frequently Asked Questions
What is Genmab ADR stock symbol?
Genmab ADR is a American stock, trading under the symbol GMAB (previously GMAB-Q on Stockchase) on the NASDAQ (GMAB). It is usually referred to as NASDAQ:GMAB or GMAB
Is Genmab ADR a buy or a sell?
In the last year, 3 stock analysts issued a Buy, Sell, or Hold rating on GMAB (previously GMAB-Q on Stockchase). 3 analysts recommended to BUY and 0 analysts recommended to SELL the stock. The latest stock analyst rating is PAST TOP PICK. Read the latest stock experts' ratings for Genmab ADR.
Is Genmab ADR a good investment or a top pick?
Genmab ADR was recommended as a Top Pick by The Panic-Proof Portfolio (Stockchase Research) on 2026-06-02. Read the latest stock experts ratings for Genmab ADR.
Why is Genmab ADR stock dropping?
Earnings reports or recent company news can cause the stock price to drop. Read stock experts' recommendations for Genmab ADR.
Is Genmab ADR worth watching?
Genmab ADR is covered by Stockchase experts and is worth watching.
What is Genmab ADR stock price?
On 2026-07-23, Genmab ADR (GMAB) stock closed at a price of $29.17.
'%20fill='%23FFB800'%3e%3cg%20id='filled-.-button'%20transform='translate(120.000000,%20413.999972)'%3e%3cpath%20d='M101.499729,2.82302245e-05%20C102.285413,-0.00432461793%20103.254164,0.496634241%20103.645655,1.25173399%20L103.712109,1.39623206%20L105.747863,6.45331817%20L111.028779,6.80428588%20C111.60867,6.84282525%20112.147242,7.1236355%20112.517275,7.58038413%20C113.223405,8.45199453%20113.142035,9.72214747%20112.357105,10.4940033%20L112.234099,10.6059323%20L108.072656,14.10894%20L109.356339,19.592529%20C109.472157,20.0872738%20109.394126,20.6085551%20109.13883,21.0455786%20C108.624329,21.9263208%20107.536956,22.2447485%20106.649713,21.8010736%20L106.511398,21.7246573%20L101.5,18.7715858%20L96.4886024,21.7246573%20C95.5790916,22.2767096%2094.4027498,21.9726757%2093.8611695,21.0455786%20C93.6058745,20.6085551%2093.5278433,20.0872738%2093.6436608,19.592529%20L94.9273443,14.10894%20L90.7659013,10.6059323%20C89.8680707,9.85015912%2089.7412886,8.49557505%2090.4827254,7.58038413%20C90.8527577,7.1236355%2091.39133,6.84282525%2091.9712215,6.80428588%20L97.2521374,6.45331817%20L99.2878908,1.39623206%20C99.6240254,0.561228427%20100.665516,-0.00460395016%20101.499729,2.82302245e-05%20Z'%20id='top-picks-.-icon-copy-7'%3e%3c/path%3e%3c/g%3e%3c/g%3e%3c/g%3e%3c/svg%3e){kind=small}
Our PAST TOP PICK with GMAB has triggered its stop at $24. To remain disciplined, we recommend covering the position at this time. Combined with our previous guidance, this will result in a net investment loss of 17%.